M Faruk Kose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
M Faruk Kose has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Gokhan Tulunay
Department of Gynecologic Oncology, Etlik Zübeyde Hanım Women's Health Teaching and Research Hospital, Ankara, Turkey
5 shared publications A Cakmak
1 shared publicationA. Al
1 shared publicationA. Hayden
1 shared publicationA. Melemed
1 shared publicationB Demir
1 shared publication
Latest Publications
- 1 March 2006
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 6 (3) , 437-443
Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma
Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the time from first relapse of their disease to death will be longer than the period from diagnosis to that first relapse. There is current evidence from prospective randomized trials that carboplatin combined with either paclitaxel or gemcitabine confers a progression-free survival advantage over platinum monotherapy for patients with platinum-sensitive relapsed ovarian cancer. Since the efficacy of paclitaxel/platinum and gemcitabine/carboplatin regimens appears to be comparable based on similar progression-free survival (both combinations confer a 3-month advantage), toxicity profiles should be taken into account when deciding on the combination to be used. The gemcitabine/carboplatin combination should be preferred in patients with underlying peripheral neuropathy. Since alopecia associated with paclitaxel can diminish the overall quality of life, the gemcitabine plus carboplatin combination may be preferable for patients in whom alopecia is a major consideration. This review provides an update on the role of the gemcitabine/carboplatin combination in platinum-sensitive recurrent ovarian cancer.
- 1 March 2006
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 6 (3) , 437-443
Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma
Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the time from first relapse of their disease to death will be longer than the period from diagnosis to that first relapse. There is current evidence from prospective randomized trials that carboplatin combined with either paclitaxel or gemcitabine confers a progression-free survival advantage over platinum monotherapy for patients with platinum-sensitive relapsed ovarian cancer. Since the efficacy of paclitaxel/platinum and gemcitabine/carboplatin regimens appears to be comparable based on similar progression-free survival (both combinations confer a 3-month advantage), toxicity profiles should be taken into account when deciding on the combination to be used. The gemcitabine/carboplatin combination should be preferred in patients with underlying peripheral neuropathy. Since alopecia associated with paclitaxel can diminish the overall quality of life, the gemcitabine plus carboplatin combination may be preferable for patients in whom alopecia is a major consideration. This review provides an update on the role of the gemcitabine/carboplatin combination in platinum-sensitive recurrent ovarian cancer.
- 1 February 2005
- Published by Elsevier in Gynecologic Oncology
- Vol. 96 (2) , 374-380
A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma
- 1 February 2005
- Published by Elsevier in Gynecologic Oncology
- Vol. 96 (2) , 374-380
A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma
- 1 January 2004
- Vol. 25 (5) , 611-4
Primary fallopian tube carcinoma: a retrospective multicenter study.
This retrospective multicenter study aimed to assess the survival and prognostic factors of primary fallopian tube carcinoma. The medical records of 29 patients with fallopian tube carcinoma from two centers were reviewed for age, stage, surgical intervention, relapse and survival. The mean age of the patients was 56 years (range, 37-76). Six patients were in Stage I (20.7%), eight cases in Stage II (27.6%), nine cases in Stage III (31%) and two cases in Stage IV (6.9%). Data on stage was not available in four cases (13.8). Fifteen patients underwent lymph node evaluation. The median follow-up was 29 months (range, 3-122). The median survival was 95 months with a 5-year survival rate of 69.7%. The median progression-free survival was 76 months with a 5-year survival rate of 51.8%. Age, stage and lymphadenectomy were found to be significant prognostic factors on overall survival.
- 1 January 2004
- Vol. 25 (5) , 611-4
Primary fallopian tube carcinoma: a retrospective multicenter study.
This retrospective multicenter study aimed to assess the survival and prognostic factors of primary fallopian tube carcinoma. The medical records of 29 patients with fallopian tube carcinoma from two centers were reviewed for age, stage, surgical intervention, relapse and survival. The mean age of the patients was 56 years (range, 37-76). Six patients were in Stage I (20.7%), eight cases in Stage II (27.6%), nine cases in Stage III (31%) and two cases in Stage IV (6.9%). Data on stage was not available in four cases (13.8). Fifteen patients underwent lymph node evaluation. The median follow-up was 29 months (range, 3-122). The median survival was 95 months with a 5-year survival rate of 69.7%. The median progression-free survival was 76 months with a 5-year survival rate of 51.8%. Age, stage and lymphadenectomy were found to be significant prognostic factors on overall survival.
- 1 January 2004
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 83 (1) , 118
Letter to the Editor
- 1 January 2004
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 83 (1) , 118
Letter to the Editor
- 1 January 1999
- Vol. 20 (2) , 131-5
Prognostic factors in stage IB-IIA cervical carcinomas treated with postoperative radiotherapy.
This study investigated the prognostic significance of age, stage, tumor size, pelvic lymph node metastasis (PLM), surgical margin invasion, overall radiotherapy time (ORT), and interval between radiotherapy and surgery (IRS) in stage IB-IIA cervical carcinoma. 100 patients treated with radical hysterectomy and postoperative radiotherapy were evaluated retrospectively. The 5-yr overall survival (OS), disease-free survival (DFS), and pelvic control rate (PC) were 83.6%, 82.8%, and 91.8%, respectively. PLM (p=0.008), IRS (p=0.01), ORT (p=0.007), and tumor size (p=0.028) were found to be significant on PC. PLM (p=0.04), ORT (p=0.04), and IRS (p=0.001) were significant on OS. PLM was significant (p=0.04) and IRS was marginally significant (p=0.06) on DFS. After multivariate analysis, PLM was significant on OS, DFS and PC. Recurrences were seen in 14 patients. According to this study PLM, IRS, and ORT are the most important prognostic factors. Recurrences outside the radiation volume leads to treatment failure.
- 1 January 1999
- Vol. 20 (2) , 131-5
Prognostic factors in stage IB-IIA cervical carcinomas treated with postoperative radiotherapy.
This study investigated the prognostic significance of age, stage, tumor size, pelvic lymph node metastasis (PLM), surgical margin invasion, overall radiotherapy time (ORT), and interval between radiotherapy and surgery (IRS) in stage IB-IIA cervical carcinoma. 100 patients treated with radical hysterectomy and postoperative radiotherapy were evaluated retrospectively. The 5-yr overall survival (OS), disease-free survival (DFS), and pelvic control rate (PC) were 83.6%, 82.8%, and 91.8%, respectively. PLM (p=0.008), IRS (p=0.01), ORT (p=0.007), and tumor size (p=0.028) were found to be significant on PC. PLM (p=0.04), ORT (p=0.04), and IRS (p=0.001) were significant on OS. PLM was significant (p=0.04) and IRS was marginally significant (p=0.06) on DFS. After multivariate analysis, PLM was significant on OS, DFS and PC. Recurrences were seen in 14 patients. According to this study PLM, IRS, and ORT are the most important prognostic factors. Recurrences outside the radiation volume leads to treatment failure.